• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

保乳手术后全身性治疗对降低局部复发的重要性：NSABP 的经验。

The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.

机构信息

UF Health Cancer Center at Orlando Health, Orlando, Florida.

出版信息

J Surg Oncol. 2014 Jul;110(1):45-50. doi: 10.1002/jso.23609. Epub 2014 Apr 12.

DOI:10.1002/jso.23609
PMID:24729388
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5604791/
Abstract

Adjuvant systemic therapy significantly reduces rates of distant recurrence and death. The effect of systemic therapy is not limited to reducing distant recurrences but also extends to reducing loco-regional recurrences, and rates of loco-regional recurrence have steadily declined over the past 25 years. This review focuses on the effect of adjuvant systemic therapy on rates of ipsilateral breast tumor recurrence following lumpectomy plus breast irradiation in several pivotal NSABP trials in early-stage breast cancer.

摘要

辅助全身治疗显著降低远处复发率和死亡率。全身治疗的效果不仅限于降低远处复发，还可降低局部区域复发，且在过去 25 年中，局部区域复发率稳步下降。本文重点关注了几项早期乳腺癌 NSABP 试验中保乳术加乳房放疗后同侧乳房肿瘤复发率的辅助全身治疗效果。

相似文献

1
The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.保乳手术后全身性治疗对降低局部复发的重要性：NSABP 的经验。
J Surg Oncol. 2014 Jul;110(1):45-50. doi: 10.1002/jso.23609. Epub 2014 Apr 12.
2
Breast conservation in breast cancer: surgical and adjuvant considerations.乳腺癌保乳治疗：手术及辅助治疗考量
Curr Opin Obstet Gynecol. 2004 Feb;16(1):31-6. doi: 10.1097/00001703-200402000-00007.
3
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.保乳术后 NSABP B-17 和 B-24 随机临床试验中同侧乳腺肿瘤局部复发的长期结果：DCIS 患者的报告。
J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.
4
[Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].保乳治疗后同侧乳腺肿瘤复发患者的临床特征与预后
Zhonghua Zhong Liu Za Zhi. 2018 May 23;40(5):352-358. doi: 10.3760/cma.j.issn.0253-3766.2018.05.007.
5
Indications for breast-preserving surgery and adjuvant therapy in early breast cancer.早期乳腺癌保乳手术及辅助治疗的适应证
Int Surg. 1994 Jan-Mar;79(1):43-7.
6
Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.早期乳腺癌保乳手术及放疗后的局部复发和远处转移
Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):25-38. doi: 10.1016/s0360-3016(98)00365-4.
7
Conservative surgery for ipsilateral breast tumor recurrence.同侧乳房肿瘤复发的保守手术。
J Surg Oncol. 2014 Jul;110(1):62-7. doi: 10.1002/jso.23629. Epub 2014 Apr 30.
8
[Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].[早期浸润性乳腺癌治疗中的循证放疗：传统临床特征与生物标志物]
Magy Onkol. 2009 Mar;53(1):7-14. doi: 10.1556/MOnkol.53.2009.1.2.
9
Lumpectomy for breast cancer: an update of the NSABP experience. National Surgical Adjuvant Breast and Bowel Project.乳腺癌保乳手术：NSABP经验更新。国家外科辅助乳腺和肠道项目
J Natl Cancer Inst Monogr. 1992(11):7-13.
10
Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials. National Surgical Adjuvant Breast and Bowel Project.用于治疗浸润性和非浸润性乳腺癌的保守手术：NSABP试验。国家外科辅助乳腺和肠道项目
World J Surg. 1994 Jan-Feb;18(1):63-9. doi: 10.1007/BF00348193.

引用本文的文献

1
Long-Term Locoregional Outcomes in a Contemporary Cohort of Young Women With Breast Cancer.当代年轻乳腺癌女性队列的长期局部区域转归
JAMA Surg. 2025 Jul 23. doi: 10.1001/jamasurg.2025.2324.
2
Locoregional Treatment for Early-Stage Breast Cancer: Current Status and Future Perspectives.早期乳腺癌的局部区域治疗：现状与未来展望。
Curr Oncol. 2023 Aug 10;30(8):7520-7531. doi: 10.3390/curroncol30080545.
3
Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer.浸润性乳腺癌患者大分割放疗的真实世界实践
Front Oncol. 2022 Feb 3;12:811794. doi: 10.3389/fonc.2022.811794. eCollection 2022.
4
Comparison of Oncoplastic Breast-Conserving Therapy and Standard Breast-Conserving Therapy in Early-Stage Breast Cancer Patients.早期乳腺癌患者保乳整形治疗与标准保乳治疗的比较
Med Sci Monit. 2021 Jan 1;27:e927015. doi: 10.12659/MSM.927015.
5
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.21 基因复发评分在 26 到 100 之间的早期乳腺癌患者接受辅助化疗加内分泌治疗的临床结局：TAILORx 随机临床试验的二次分析。
JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794.
6
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.临床和基因组风险指导乳腺癌辅助治疗的应用。
N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.
7
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.基于 21 基因表达检测的乳腺癌辅助化疗。
N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.
8
Tumor cell expression of CD163 is associated to postoperative radiotherapy and poor prognosis in patients with breast cancer treated with breast-conserving surgery.肿瘤细胞 CD163 的表达与保乳手术后接受放疗的乳腺癌患者的术后放疗和预后不良相关。
J Cancer Res Clin Oncol. 2018 Jul;144(7):1253-1263. doi: 10.1007/s00432-018-2646-0. Epub 2018 May 3.
9
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23.T1-2N1 三阴性乳腺癌患者的保乳治疗与乳房切除术的比较：KROG 14-18 和 14-23 的汇总分析。
Cancer Res Treat. 2018 Oct;50(4):1316-1323. doi: 10.4143/crt.2017.575. Epub 2018 Jan 8.
10
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.CALOR试验中二次局部区域复发后的预后较差。
Ann Surg Oncol. 2017 Feb;24(2):398-406. doi: 10.1245/s10434-016-5571-y. Epub 2016 Sep 23.

本文引用的文献

1
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.乳腺癌局部区域性孤立复发的化疗（CALOR）：一项随机试验。
Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.
2
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.新辅助化疗后局部区域复发的预测因素：国家外科辅助乳腺和肠道项目 B-18 和 B-27 联合分析的结果。
J Clin Oncol. 2012 Nov 10;30(32):3960-6. doi: 10.1200/JCO.2011.40.8369. Epub 2012 Oct 1.
3
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.辅助他莫昔芬可降低激素受体阳性导管原位癌女性的后续乳腺癌风险：基于 NSABP 协议 B-24 的研究。
J Clin Oncol. 2012 Apr 20;30(12):1268-73. doi: 10.1200/JCO.2010.34.0141. Epub 2012 Mar 5.
4
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
5
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访：NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
6
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.保乳术后 NSABP B-17 和 B-24 随机临床试验中同侧乳腺肿瘤局部复发的长期结果：DCIS 患者的报告。
J Natl Cancer Inst. 2011 Mar 16;103(6):478-88. doi: 10.1093/jnci/djr027. Epub 2011 Mar 11.
7
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.在五项国家外科辅助乳腺和肠道项目（NSABP）关于淋巴结阴性乳腺癌的方案中，接受保乳治疗的患者同侧乳腺肿瘤复发及局部区域复发后的预后情况。
J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.
8
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.在五项美国国立外科辅助乳腺和肠道项目的淋巴结阳性辅助性乳腺癌试验中，同侧乳腺肿瘤复发及局部区域复发后的预后情况。
J Clin Oncol. 2006 May 1;24(13):2028-37. doi: 10.1200/JCO.2005.04.3273.
9
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.曲妥珠单抗联合辅助化疗用于可手术的HER2阳性乳腺癌
N Engl J Med. 2005 Oct 20;353(16):1673-84. doi: 10.1056/NEJMoa052122.
10
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.HER2阳性乳腺癌辅助化疗后使用曲妥珠单抗。
N Engl J Med. 2005 Oct 20;353(16):1659-72. doi: 10.1056/NEJMoa052306.